Cosentyx
Targeted IL-17A inhibition for plaque psoriasis and inflammatory skin disease.
Cosentyx (secukinumab) blocks interleukin-17A, one of the central signals that drives plaque psoriasis, psoriatic arthritis and axial inflammation. It targets a specific inflammatory pathway rather than acting like a conventional broad immunosuppressant. Response and adverse effects still vary, so infection history and other health factors are reviewed before treatment.
- Injection
- Route
- 4 weekly
- Interval
- 4–12 wks
- First results
- IL-17A
- Target
- Pre-treatment screening
- Weekly induction
- 4-weekly maintenance
- Severity scoring
Diagnosed first, treated second.
Candidacy is decided on disease severity, prior therapy, screening bloodwork and infection history. For plaque psoriasis, treatment is usually delivered by subcutaneous injection with a loading phase followed by maintenance dosing. The exact dose and schedule depend on the indication, age, weight and current prescribing information.
- 01Pre-treatment screening
- 02Weekly induction
- 034-weekly maintenance
- 04Severity scoring
- 05Self-injection training
- Moderate to severe plaque psoriasis
- Inadequate response to topicals or phototherapy
- Psoriatic arthritis with skin involvement
- Intolerance to methotrexate or ciclosporin
- No active infection or untreated tuberculosis
How the treatment works
A sequence, not a single appointment — each step informs the next.
- 01
Eligibility review
Severity scoring, prior treatment history and a full assessment of comorbidities.
- 02
Screening
Tuberculosis screening, hepatitis serology and baseline bloodwork before the first dose.
- 03
Induction
Weekly loading injections for five weeks, taught for confident self-administration at home.
- 04
Maintenance
One injection every four weeks with scored reviews and dose continuation decided on response.
Results measured, not promised.
What to expect
- 01Plaque improvement may begin within the first treatment months
- 02Relief from itch, scaling and plaque thickness
- 03Reduced joint pain in psoriatic arthritis
- 04Sustained control may be possible with maintenance dosing
- 05Monitoring tailored to history, indication and local guidance
Results, treatment timing and recovery vary by diagnosis and individual factors. This page is educational and does not replace a medical consultation or guarantee an outcome. Prescription treatment is selected after reviewing current product information, approved indications, infection and vaccination history, other medicines and drug-specific risks.
Begin with a diagnosis,
not a guess.
Share a few details and the clinic will reply with available consultation times for cosentyx — one-to-one with Dr. Arely.
- Response
- Within 24 hours
- Consultation
- One-to-one, 45 min
- Assessment
- Trichoscopy included
- Location
- Dr. Arely Clinic
Frequently asked
Some patients notice improvement in the first month, while fuller response assessment commonly takes several months.
Yes. You are taught injection technique and storage in clinic, and supported through the first cycles.
Infection risk, vaccination status and any history of inflammatory bowel disease are reviewed. IL-17 inhibitors may worsen or newly trigger inflammatory bowel disease in some patients.
Disease usually returns gradually. Any pause is planned rather than abrupt, with a maintenance strategy agreed first.